Publicacións en colaboración con investigadores/as de University Hospital of Zurich (3)

2022

  1. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

    Annals of Oncology, Vol. 33, Núm. 2, pp. 181-192

2020

  1. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

    Annals of Oncology, Vol. 31, Núm. 12, pp. 1734-1745

  2. The role of the liquid biopsy in decision-making for patients with non-small cell lung cancer

    Journal of Clinical Medicine, Vol. 9, Núm. 11, pp. 1-19